Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Biotech startup stories

Nov 17, 2026

Marrow raises $173M to develop siRNA alternative to gene therapy for sickle cell

Startup Marrow Therapeutics raised $173 million to develop an siRNA-based infusion therapy for sickle cell disease and beta thalassemia, positioning it as a more accessible alternative to approved one-time CRISPR and gene therapy treatments.

Nov 17, 2026·3 sources
00
Nov 16, 2026

Eli Lilly acquires Calytrix Bio for up to $1.5B in rare blood cancer push

Eli Lilly agreed to acquire Calytrix Bio for up to $1.5 billion to expand development of treatments for rare blood cancers known as myeloproliferative neoplasms, its 14th or 15th acquisition of 2026.

Nov 16, 2026·3 sources
00
Nov 15, 2026

Oyster Therapeutics raises $60M for brain-penetrating small molecule degraders

Brain-focused startup Oyster Therapeutics secured $60 million to advance its lead program targeting pathological tau in Alzheimer's disease, with Eli Lilly participating in the round.

Nov 15, 2026·3 sources
00
Nov 7, 2026

T-Therapeutics raises $133M Series B for T-cell therapies in cancer and autoimmune disease

UK-based T-Therapeutics closed a $133 million Series B funding round led by Advent Life Sciences and British Business Bank to advance T-cell therapies targeting cancer and autoimmune diseases.

Nov 7, 2026·2 sources
00
Nov 5, 2026

Alethio Therapeutics raises $90M Series A for rare blood cancer antibody

Oxford spinout Alethio Therapeutics secured $90 million in Series A funding to advance an antibody treatment for myeloproliferative neoplasms, a group of rare blood cancers.

Nov 5, 2026·2 sources
00

T-Therapeutics raises $133M Series B for cancer and autoimmune T cell receptor drugs

UK biotech T-Therapeutics has closed a $133 million Series B round backed by Johnson & Johnson, Merck KGaA, Eli Lilly, and Sanofi to advance T cell receptor therapies for cancer and autoimmune diseases into clinical development.

Nov 5, 2026·2 sources
00
Nov 1, 2026

Setara Biosciences launches with $90M for rare disease drug development

Setara Biosciences has started operations with $90 million in funding and a lead drug candidate already in clinical trials for Charcot-Marie-Tooth disease type 2C and overactive bladder.

Nov 1, 2026·4 sources
00
Oct 29, 2026

Dren Bio raises $350 million for blood cancer drug ahead of potential 2027 launch

California biotech Dren Bio secured $350 million in funding to advance its lead blood cancer therapy toward a potential market launch by the end of 2027.

Oct 29, 2026·3 sources
00

Flagship Pioneering merges Etiome, Cellarity and Empress Therapeutics into Etcelera

Biotechnology startup creator Flagship Pioneering is combining three of its portfolio companies—Etiome, Cellarity, and Empress Therapeutics—into a new venture called Etcelera. The merged company will use artificial intelligence and drug discovery tools to predict which experimental medicines might succeed in clinical trials.

Oct 29, 2026·2 sources
00
Oct 28, 2026

Formation raises $600 million to accelerate AI drug development

AI biotech startup Formation Bio raised $600 million to acquire or license stalled drug candidates and use AI to accelerate clinical trials, addressing what it sees as the real bottleneck in drug development.

Oct 28, 2026·2 sources
00
Oct 27, 2026

Ferring to acquire fertility startup Gameto for up to $1.38B

Ferring Pharmaceuticals has signed an agreement to acquire fertility startup Gameto in a deal worth up to $1.3825 billion, expanding its reproductive health portfolio.

Oct 27, 2026·2 sources
00
Oct 23, 2026

Star Therapeutics raises $200 million to advance pipeline after spinout successes

Star Therapeutics has secured $200 million in private financing to advance its preclinical programs into clinical trials and expand its pipeline. The funding follows the company's successful track record of spinning out companies including Vega and Electra, with Incyte acquiring one of its spinouts in July 2026.

Oct 23, 2026·5 sources
00
Oct 21, 2026

OpenAI and Peter Thiel's Founders Fund invest in Coherence Neuro's cancer-detecting brain implant

Coherence Neuro has raised $45 million in funding from OpenAI's venture capital arm and Founders Fund to develop a brain implant designed to detect and treat cancer. The coin-sized device monitors tumor activity through neural signals.

Oct 21, 2026·2 sources
00
Oct 16, 2026

Estuary Biotherapeutics emerges with $103 million for kidney disease gene therapies

Estuary Biotherapeutics, a California-based biotech developing gene therapies for kidney disease, officially launched with $103 million in funding and a management team of former Biogen leaders backed by investors including Biogen.

Oct 16, 2026·2 sources
00
Aug 24, 2026

Bristol Myers ends blood cancer drug partnership with Cellares

Bristol Myers Squibb terminated its partnership with cell therapy startup Cellares to expand manufacturing of its personalized blood cancer therapy, prompting Cellares to lay off 100 employees.

Aug 24, 2026·2 sources
00
Aug 12, 2026

Boulevard Bio launches with $65M to develop targeted autoimmune antibody therapies

Boulevard Bio emerged from stealth with $65 million in funding from Deerfield Management, co-founded by renowned autoimmune researcher Georg Schett and former Sanofi CSO Frank Nestle. The startup is advancing three antibody programs targeting autoimmune diseases, with its lead candidate BLVD101 in early clinical development for IgA nephropathy.

Aug 12, 2026·4 sources
00

Top claims

  • ▪Unlike stem cell gene therapies that require one-time laboratory cell modification, Marrow Therapeutics' MAR-101 can be administered via repeated injections should treatment effects wane
  • ▪Marrow Therapeutics Chief Executive Officer Romesh Subramanian stated that the company is developing MAR-101 to provide a safer, efficacious, and globally accessible treatment alternative for patients with inherited blood disorders
  • ▪Marrow Therapeutics plans to use its $173 million funding to advance its lead drug candidate MAR-101 for sickle cell disease and beta thalassemia and to build out its manufacturing capabilities

People involved

Sam AltmanPeter Thiel

Subtopics

Venture capital funding11Drug development10Biotechnology6Cancer & Oncology5Clinical trials5Autoimmune disease treatments4Eli Lilly4Hematology & Blood Cancers4Pharmaceutical Industry4Rare diseases4AI in healthcare3Biotech innovation3Drug discovery3Mergers & acquisitions (M&A)3Mergers and acquisitions3AI applications2AI drug discovery2Autoimmune disease2Cancer immunotherapy2Drug Approval and Clinical Trials2Drug Policy, Pricing & Approval2Gene therapy2Immunotherapy2Pharma2

Related timelines

Payments

118 stories

Russia-Ukraine war

136 stories

Trump administration

161 stories

Congress

110 stories

Crypto hacks

100 stories